Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

NCT04463771 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: retifanlimab
DRUG: epacadostat
DRUG: pemigatinib
DRUG: INCAGN02385
DRUG: INCAGN02390

Sponsor

Incyte Corporation

Collaborators

[object Object]
[object Object]